GlassScriptPhysician profile
Rafael G Torres
NPI 1285696716
$3,321.81
in general payments reported to CMS, 2019-2025
26 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,477 · 2020: $278 · 2021: $344 · 2022: $183 · 2023: $261 · 2024: $499 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $585.29 | 2020-2024 | Talicia |
| Lilly USA, LLC | $523.44 | 2019-2025 | |
| Amgen INC. | $340.31 | 2023-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $309.83 | 2019-2025 | Pifeltro |
| Janssen Biotech, INC. | $301.12 | 2019-2023 | Symtuza |
| Viiv Healthcare Company | $289.77 | 2019 | |
| Cequr Corporation | $136.27 | 2025 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $121.75 | 2024 | |
| Napo Pharmaceuticals INC | $119.73 | 2019 | |
| Gilead Sciences, INC. | $111.23 | 2019 | |
| Theratechnologies INC. | $95.89 | 2019-2021 | |
| Janssen Products, LP | $80.72 | 2019 | |
| Rigel Pharmaceuticals, INC. | $46.36 | 2024 | Rezlidhia, Tavalisse |
| Corcept Therapeutics | $34.33 | 2024 | Korlym |
| Sanofi-Aventis U.S. LLC | $32.27 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $28.60 | 2024 | |
| Mylan Pharmaceuticals INC. | $23.00 | 2019 | |
| Glaxosmithkline, LLC. | $22.80 | 2020 | |
| Optos, INC. | $20.35 | 2020 | |
| Radius Health, INC. | $17.02 | 2023 | Tymlos |
| Eyevance Pharmaceuticals LLC | $14.77 | 2021 | |
| Hikma Pharmaceuticals USA | $14.77 | 2021 | |
| Abbott Laboratories | $14.31 | 2021 | |
| Zyla Life Sciences, INC. | $13.15 | 2019 | |
| Allergan, INC. | $13.10 | 2020 | |
| Mission Pharmacal Company | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.